EyePoint Q2 revenue $9.1M, net loss $22.9M; sells YUTIQ for $82.5M; Phase 2 data due Dec 2023

EyePoint, Inc.

2023-Q2 EPS reported -$1.17 revenue$16,788,000

Net product revenue fell to $5.3M from $11.3M due to YUTIQ sale and DEXYCU discontinuation.
Sold YUTIQ franchise to Alimera Sciences for $82.5M cash plus future royalties; retired all bank debt.
Phase 2 DAVIO 2 (wet AMD) topline data due Dec 2023; no drug-related SAEs reported to date.
Phase 2 PAVIA (NPDR) fully enrolled (77 patients), topline expected Q2 2024.
Jay S. Duker appointed President and CEO; Nancy Lurker transitioned to Executive Vice Chair of Board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EyePoint, Inc. reported second quarter ended June 30, 2023 results: revenue total net revenue was $9.1 million.

Period: second quarter ended June 30, 2023
Revenue: total net revenue was $9.1 million
Result: reported results

Exact text from the filing

For the second quarter ended June 30, 2023, total net revenue was $9.1 million compared to $11.6 million for the quarter ended June 30, 2022.

View on SEC.gov

Browse all earnings releases →

EyePoint, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-036770

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.